Biomarker-Driven Lung Cancer | Clinical

Pembrolizumab Alone Shows Best Response in NSCLC With 90% or Higher PD-L1 Expression

June 07, 2022

Treatment with pembrolizumab monotherapy demonstrated the best response in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more, according to a correlative analysis conducted with 3-years of follow-up.

Community Health Systems Test for Recommended Cancer Biomarkers More Often Than Independent Practices

May 26, 2022

In patients with advanced non-squamous non–small cell lung cancer treated within large community health systems in the United States , biomarker testing appeared to be significantly higher compared with independent community practices, research shows.